TG Therapeutics to Host Second Quarter 2022 Financial Results and Business Update Conference Call The conference call will be held Monday, August 8, 2022 at 8:30 a.m. ET


NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday, August 8, 2022 at 8:30 a.m. ET to discuss results for the second quarter of 2022. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.

To participate in the conference call, please call 1-877-407-8029 (US), 1-201-689-8029 (outside the US), Conference Title: TG Therapeutics. A live webcast of this presentation will be available on the Events page, located in the Investors and Media section, of the Company’s website at An audio recording of the conference call will also be available for replay on www.tgtherapeutics.comfor a period of 30 days after the appeal.

TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.

TG Therapeutics is a biopharmaceutical company focused on acquiring, developing and commercializing novel treatments for B-cell diseases. In addition to a research pipeline comprising several investigational drugs, TG has completed a Phase 3 program for the ublituximab, an investigational genetically engineered monoclonal antibody that targets a unique epitope on CD20-expressing B cells, to treat patients with relapsing forms of multiple sclerosis (RMS). For more information, visitwww.tgtherapeutics.comand follow us on Twitter@TGTherapeuticsandLinkedIn.


Investor Relations
E-mail: [email protected]
Phone: 1.877.575.TGTX (8489), Option 4

Media Relations:
E-mail: [email protected]
Phone: 1.877.575.TGTX (8489), Option 6

main logo

Source link


Comments are closed.